clinical trial · NCT04767373
Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)
Merck Sharp & Dohme LLC·phase3·completed·n = 3,632
Respiratory Syncytial Virus InfectionClesrovimabPlacebo
brief summary
The primary objectives of this phase 2b/3 double-blind, randomized, placebo-controlled study are to evaluate the efficacy and safety of clesrovimab in healthy pre-term and full-term infants. It is hypothesized that clesrovimab will reduce the incidence of respiratory syncytial virus (RSV)-associated medically attended lower respiratory infection (MALRI) from Days 1 through 150 postdose compared to placebo.
started
Apr 7, 2021
primary completion
Jul 9, 2024
completion
Jul 9, 2024
last updated
Feb 11, 2026
official title
A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol